Please provide your email address to receive an email when new articles are posted on . Direct-acting antivirals for hepatitis C have dominated hepatitis research for the past decade and have ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...

Future Microbiol. 2010;5(3):393-402. While these new findings cement the relationship between the structure and replication of HDV and plant viroid RNAs, they still leave open the question of whether ...

This story is part of our series on viroids and virusoids, small infectious RNAs. The story is also the second installment in a series on hepatitis D virus, a virusoid-like pathogen that causes ...

This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the sixth installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

A team led by Professor Patrick Labonté at the Institut National de la Recherche Scientifique (INRS) in Montreal, Canada has identified the role of a key process in the replication cycle of the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted Eiger BioPharmaceuticals fast track designation for lonafarnib in combination with Norvir ...

Promising new viral hepatitis data show that entry inhibitors a new mechanism of action for drugs to treat viral hepatitis could provide the first new hepatitis B and hepatitis D treatments for many ...

Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib – Results Presented at American Association for the Study of Liver Diseases (AASLD) ...

Immigration is fuelling a new reservoir of hepatitis D virus (HDV) in Europe, and hepatitis D still represents an important medical problem in the USA. The disease continues to be a major medical ...